Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company, announced that Nature Methods, one of the world's leading scientific journals, has selected spatial proteomics as its prestigious "Method of the Year 2024", recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in spatial proteomics, with the industry's largest installed base of 1300 instruments and nearly 1600 publications citing its technologies, Akoya celebrates this milestone as a testament to the technology's impact and reaffirms its dedication to driving innovation in this rapidly evolving field.
馬爾堡,馬薩諸塞州,2024年12月09日(環球新聞)-- Akoya生物科學公司(納斯達克:AKYA)("Akoya"),空間生物學公司,宣佈世界領先的科學期刊之一《自然方法》已將空間蛋白組學選爲其2024年"年度方法",以此認可這一方法在推動生物研究和醫學方面的變革潛力。作爲空間蛋白組學的全球領導者,Akoya擁有1300台儀器的行業最大裝機基礎和近1600篇引用其技術的出版物,該公司慶祝這一里程碑,證明了這一技術的影響,並重申了其在快速發展的領域推動創新的承諾。
Spatial proteomics provides scientists with the ability to map the spatial distribution of proteins within cells and tissues, revealing insights into cellular mechanisms, tissue architecture, and disease progression. Its applications span oncology, immunotherapy, neuroscience, drug development, and more, delivering unprecedented resolution and depth to biological research. Akoya offers complete end-to-end spatial proteomic solutions with instruments, reagents, software and services serving customers that span from discovery to diagnostics. The PhenoCycler-Fusion is an ultrahigh-plex platform for spatial discovery while the PhenoImager HT is a high-throughput platform for translational and clinical applications.
空間蛋白組學爲科學家提供了繪製細胞和組織內蛋白空間分佈的能力,揭示了細胞機制、組織結構和疾病進展的見解。其應用涵蓋腫瘤學、免疫療法、神經科學、藥物開發等多個領域,爲生物研究提供了前所未有的分辨率和深度。Akoya提供完整的端到端空間蛋白組學解決方案,包括儀器、試劑、軟件和服務,服務於從發現到診斷的客戶。PhenoCycler-Fusion是一種超高通量的平台,用於空間發現,而PhenoImager Ht是用於轉化和臨床應用的高通量平台。
"At Akoya, we are proud to be at the forefront of spatial proteomics, revolutionizing how scientists understand complex biological systems," said Brian McKelligon, CEO of Akoya Biosciences. "Spatial proteomics being recognized by Nature Methods underscores the pivotal role this method plays in driving scientific breakthroughs and further validates Akoya's singular focus on driving continued advancement in our platforms for the betterment of our customers and ultimately patients."
"在Akoya,我們自豪地站在空間蛋白組學的最前沿,徹底改變科學家理解複雜生物系統的方式,"Akoya生物科學公司首席執行官布萊恩·麥凱利根(Brian McKelligon)說。"空間蛋白組學被《自然方法》認可,強調了這一方法在推動科學突破中發揮的關鍵作用,並進一步驗證了Akoya專注於推動我們平台持續進步的獨特定位,以造福我們的客戶,最終造福患者。"
Customer and KOL Perspectives
客戶及關鍵意見領袖觀點
Esteemed researchers and thought leaders in the scientific community have recognized the transformative potential of spatial proteomics and the contributions of Akoya Biosciences in this space:
在科學社區中,傑出的研究人員和思想領袖們認識到了空間蛋白質組學的變革潛力,以及Akoya Biosciences在這一領域的貢獻:
Dr. Garry Nolan, Rachford and Carlota Harris Professor, Department of Pathology, Stanford University, Co-founder of Akoya Biosciences and Chair of Akoya's Scientific Advisory Board commented:
斯坦福大學病理學系的拉克福德和卡洛塔·賀錦麗教授、Akoya Biosciences的聯合創始人和Akoya科學顧問委員會主席加里·諾蘭博士評論道:
"Spatial proteomics represents a paradigm shift in our ability to understand complex tissue architecture and cellular interactions in their native context. Akoya's technology allows us to explore the intricate relationships between cells and their environments, unlocking insights that were previously unattainable and driving breakthroughs in both basic science and clinical applications."
「空間蛋白質組學在我們理解複雜組織結構和細胞相互作用的能力上代表了一次範式轉變。Akoya的技術讓我們能夠探索細胞與其環境之間的複雜關係,揭示了之前不可獲得的洞見,推動了基礎科學和臨床應用的突破。」
Dr. Arutha Kulasinghe, Associate Professor and Clinical-oMx Lab Head, Frazier Institute, University of Queensland commented:
昆士蘭大學Frazier研究所的副教授及臨床oMx實驗室負責人阿魯莎·庫拉辛赫博士評論道:
"Integrating ultrahigh-plex spatial proteomics into our research has been revolutionary. The platforms offered by Akoya enable us to unravel protein networks with precision and scale, opening new avenues in studying immune response and disease pathways."
「將超高通量空間蛋白組學整合到我們的研究中是一次革命性的突破。Akoya提供的平台使我們能夠精確和大規模地解開蛋白質網絡,爲研究免疫反應和疾病通路開闢了新的途徑。」
Driving Innovation and Delivering Impact
推動創新,產生影響
Akoya has consistently led the evolution of spatial proteomics, delivering impactful contributions to the global research community. The company:
Akoya不斷引領空間蛋白組學的發展,爲全球研究社區帶來了重大的貢獻。該公司:
- Delivers a spectrum of solutions, ranging from multiplex immunofluorescence technologies measuring 6-8 biomarkers to ultrahigh-plex systems capable of profiling over 100 analytes in a single experiment.
- Contributes the largest data volume to flagship global initiatives such as the Human Tumor Atlas Network (HTAN) and HuBMAP (Human BioMolecular Atlas Program).
- Powers multi-site collaborations like the MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) program, fostering standardization and scalability in high-impact research initiatives.
- 提供一系列解決方案,從測量6-8個生物標誌物的多重免疫熒光技術到能夠在單次實驗中分析超過100個分析物的超高通量系統。
- 爲人類腫瘤圖譜網絡(HTAN)和人類生物分子圖譜計劃(HuBMAP)等旗艦全球計劃提供了最大的數據信息。
- 支持像MANIFESt(免疫治療特徵多組學分析,證明成功與毒性)這樣的多地點合作,促進高影響力研究項目的標準化和可擴展性。
These innovations have enabled researchers worldwide to uncover critical insights into tissue biology, contributing to potential breakthroughs in areas such as precision medicine, biomarker discovery, and therapeutic development.
這些創新使全球的研究人員能夠揭示組織生物學的重要見解,爲精準醫療、生物標誌物發現和治療開發等領域的潛在突破做出貢獻。
Forward-Looking Statements
前瞻性聲明
This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential impact of spatial biology in advancing biological research and medicine, the potential of our products and services, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services and other statements regarding our business strategies and plans and objectives for future operations.
本新聞稿包含基於管理層信念和假設以及當前可用信息所做的前瞻性陳述。除歷史事實外,本發佈中包含的所有陳述均爲前瞻性陳述,包括關於空間生物學在推動生物研究和醫學中的潛在影響、我們產品和服務的潛力、我們開發、商業化和實現當前及計劃產品和服務的市場接受能力及其他關於我們業務策略、計劃和未來運營目標的陳述。
In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
在某些情況下,您可以通過"可能","將","或許","會","應當","期望","打算","規劃","預期","相信","估計","預測","計劃","潛在","持續","不斷"或這些詞的否定形式,或其他類似術語來識別前瞻性聲明,儘管並非所有前瞻性聲明都含有這些詞。這些聲明涉及風險、不確定性和可能導致實際結果、活動水平、績效或成就與這些前瞻性聲明所表達或暗示的信息有實質不同的其他因素。這些風險、不確定性和其他因素在我們不時向證券交易委員會提交的文件中的"風險因素","管理討論和分析財務狀況和經營業績"和其他地方有所描述。我們提醒您,前瞻性聲明是基於我們目前已知的事實和因素以及我們對未來的預測的結合,對於這些預測,我們不能確定。因此,前瞻性聲明可能不準確。本新聞稿中的前瞻性聲明代表我們截至本文日期的看法。我們除法律要求外,對於任何原因不會更新任何前瞻性聲明。
About Akoya Biosciences
關於Akoya Biosciences
As The Spatial Biology Company, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit .
作爲空間生物學公司,Akoya生命科學的使命是通過空間表型的力量將上下文帶入生物學和人類健康世界。該公司提供全面的單細胞成像解決方案,使研究人員能夠通過空間背景表型細胞,並可視化它們的組織和相互作用,以影響疾病進展和對治療的反應。Akoya提供完整的空間表型解決方案,以滿足發現、轉化和臨床研究中研究人員多樣化的需求:PhenoCode Panels和PhenoCycler,PhenoImager Fusion和PhenoImager Ht儀器。要了解更多關於Akoya的信息,請訪問 。
CONTACT: Investor Contact:
Priyam Shah
investors@akoyabio.com
Media Contact:
Christine Quern
cq@christinequern.com
投資者聯繫方式:
Priyam Shah
investors@akoyabio.com
媒體聯繫:
克莉絲汀·查恩
cq@christinequern.com
譯文內容由第三人軟體翻譯。